Abstract: The present disclosure relates to the treatment of lung, liver, and/or kidney injury, by administering to a subject in need thereof a therapeutically effective amount of a (very) long acting C-type natriuretic peptide (CNP), CNP derivative, (very) long acting CNP derivative, or (very) long acting CNP receptor (NPRB) agonist. The disclosure also relates to the treatment of non-cardiovascular causes of low blood oxygenation, elevated levels of inflammatory cells in the lung, pulmonary edema, sepsis, bacteremia, fibrosis in general, and/or interstitial lung disease using the same.

Abstract: The present disclosure relates to methods of treating a subject having abnormal vasculature by administering to the subject a therapeutically effective bolus dose of a composition including a long acting C-type natriuretic peptide (CNP), CNP derivative, long acting CNP derivative, long acting CNP receptor (NPRB) agonist, or any combination thereof. The present disclosure further relates to treating a subject in need of an increase in cytotoxic T cell and/or NK cell activity by administering to the subject a therapeutically effective bolus dose of a composition including a long acting C-type natriuretic peptide (CNP), CNP derivative, long acting CNP derivative, long acting CNP receptor (NPRB) agonist, or any combination thereof.

Abstract: The invention relates to a composition containing catechins found in green tea, to pharmaceutical compositions and medical devices comprising the composition and to the use of these compositions and medical devices in the treatment of coronavirus infections, especially infection with SARS-CoV-2.

Abstract: The present disclosure is intended to enhance various effects of a green tea extract such as catechin in the most effective manner. The ratio (B/A) of epigallocatechin gallate (A) contained in the green tea extract and flavanone glycoside (B) contained in the citrus extract is 0.2<B/A<1.6, or a ratio (C/A) of epigallocatechin gallate (A) and eriocitrin (C) contained in the citrus extract is 0.2<C/A<0.5.

Abstract: A DPP-IV inhibitor and a food with functional claims, which comprises methylated catechin as a novel active ingredient, are provided.

Abstract: A 67 kDa laminin receptor agonist containing an oolong tea polymerized polyphenol or a derivative thereof as an active ingredient.

Abstract: The present invention provides a composition comprising a tea extract or a catechin and a citrus fruit extract or a flavanone or a glycoside thereof.

Abstract: An object is to find out a safe component that can effectively exhibit action including the protection of a brain function, the prevention or alleviation of a reduction in cognitive ability, and the prevention or alleviation of dementia. A component of a plant body of a hybrid between Camellia sinensis and Camellia taliensis is contained as an active component. The hybrid between Camellia sinensis and Camellia taliensis is preferably Sunrouge. A tea leaf extract of the plant body of the hybrid between Camellia sinensis and Camellia taliensis is preferably contained.

Abstract: An object of the present invention is to find a component that is safe and is capable of effectively exerting various effects such as prevention or amelioration of diabetes, prevention or amelioration of metabolic syndrome, amelioration of insulin resistance, inhibition of an increase in a postprandial blood sugar level, and inhibition of ?-glucosidase activity. The present invention provides agents for preventing or ameliorating diabetes or the like, the agents including a component of a hybrid plant of Camellia sinensis and Camellia taliensis as an active ingredient. The hybrid plant is preferably Sun Rouge, and each of the agents preferably includes a tea leaf extract of the hybrid plant.

Abstract: The present invention provides a composition comprising a tea extract or a catechin and a citrus fruit extract or a flavanone or a glycoside thereof.

Abstract: Disclosed is a medicament characterized by the combination of: epigallocatechin gallate, methylated epigallocatechin gallate, or a pharmacologically permitted salt thereof; and a phosphodiesterase inhibitor.

Abstract: Disclosed is a medicament characterized by the combination of: epigallocatechin gallate, methylated epigallocatechin gallate, or a pharmacologically permitted salt thereof; and a phosphodiesterase inhibitor.

Abstract: It is intended to provide a novel method of screening a drug with the use of a 67 kDa laminin receptor and a drug obtained thereby.

Abstract: It is intended to provide a novel method of screening a drug with the use of a 67 kDa laminin receptor and a drug obtained thereby.

Abstract: The present invention provides a novel agent/composition using a bioregulatory function of a food ingredient. Namely, it is intended to provide an allergy suppressive agent comprising chrysin, more specifically speaking, a histamine release inhibitory agent comprising chrysin; a composition comprising chrysin that is a composition for treating a disease or condition relating to the production of IgE; a composition comprising chrysin that is a composition for treating a disease or condition relating to a high-affinity IgE receptor; and a composition comprising chrysin that is a composition for treating a disease or condition relating to the overproduction of IL-4. It is preferable that the allergy suppressive agent and histamine release inhibitory agent according to the present invention further comprise apigenin.

Abstract: It is intended to provide a novel method of screening a drug with the use of a 67 kDa laminin receptor and a drug obtained thereby.

Abstract: This invention is to provide an agent for therapy and prevention of allergic diseases which has no adverse action, shows a high safety even by administration for a long period and is able to be utilized to food and/or beverage, cosmetics, etc. which are used daily. To be specific, it provides antiallergic agent and anti-inflammatory agent characterized in containing at least one polyphenol selected from strictinin and methylated derivatives thereof as an effective ingredient; a method for the addition of an antiallergic agent for oral administration or an anti-inflammatory agent for oral administration which is characterized in containing at least one polyphenol selected from strictinin and methylated derivatives thereof as an effective ingredient to food and/or beverage for prevention, suppression and mitigation of allergic symptoms or inflammatory symptoms.

Abstract: This invention is to provide an agent for therapy and prevention of allergic diseases which has no adverse action, shows a high safety even by administration for a long period and is able to be utilized to food and/or beverage, cosmetics, etc. which are used daily. To be specific, it provides antiallergic agent and anti-inflammatory agent characterized in containing at least one polyphenol selected from strictinin and methylated derivatives thereof as an effective ingredient; a method for the addition of an antiallergic agent for oral administration or an anti-inflammatory agent for oral administration which is characterized in containing at least one polyphenol selected from strictinin and methylated derivatives thereof as an effective ingredient to food and/or beverage for prevention, suppression and mitigation of allergic symptoms or inflammatory symptoms.

Abstract: This invention is to provide an agent for therapy and prevention of allergic diseases which has no adverse action, shows a high safety even by administration for a long period and is able to be utilized to food and/or beverage, cosmetics, etc. which are used daily. To be specific, it provides antiallergic agent and anti-inflammatory agent characterized in containing at least one polyphenol selected from strictinin and methylated derivatives thereof as an effective ingredient; a method for the addition of an antiallergic agent for oral administration or an anti-inflammatory agent for oral administration which is characterized in containing at least one polyphenol selected from strictinin and methylated derivatives thereof as an effective ingredient to food and/or beverage for prevention, suppression and mitigation of allergic symptoms or inflammatory symptoms.

Abstract: This invention is to provide an agent for therapy and prevention of allergic diseases which has no adverse action, shows a high safety even by administration for a long period and is able to be utilized to food and/or beverage, cosmetics, etc. which are used daily. To be specific, it provides antiallergic agent and anti-inflammatory agent characterized in containing at least one polyphenol selected from strictinin and methylated derivatives thereof as an effective ingredient; a method for the addition of an antiallergic agent for oral administration or an anti-inflammatory agent for oral administration which is characterized in containing at least one polyphenol selected from strictinin and methylated derivatives thereof as an effective ingredient to food and/or beverage for prevention, suppression and mitigation of allergic symptoms or inflammatory symptoms.